HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.HCW Biologics Inc. reported Q2 2026 revenue of $135.6K and a net loss of $(15.37M). Diluted EPS narrowed to $(11.58) from $(40.72) YoY. The company recognized $6.7M in H1 2026 from the Trimmune license. Clinically, HCW9302 showed positive Phase 1 results for alopecia areata. HCW Biologics is repositioning HCW9201/9206 as manufacturing reagents and preparing IND studies for HCW11-018b, aiming for Phase 1 in H1 2027.
HCW Biologics Inc. reported second-quarter 2026 results with revenue of $135.6K and a net loss attributable to common stockholders of $(15.37M); diluted loss per share narrowed to $(11.58) versus $(40.72) a year earlier.
Financial Highlights
- Revenue: $135.6K for Q2 2026, versus $6.6K in the year-ago quarter (increase of $129.0K YoY).
- Net income: Net loss attributable to common stockholders of $(15.37M) for Q2 2026, versus net loss of $(12.08M) in the year-ago quarter (worse YoY).
- Diluted EPS: $(11.58) for Q2 2026, versus $(40.72) in the year-ago quarter (loss narrowed YoY).
Business Highlights
- Revenue growth and licensing: Recognized $6.7M in H1 2026 from the Trimmune license, including a $3.5M upfront payment and deferred services revenue.
- Clinical momentum: Reported a positive preliminary Phase 1 readout for HCW9302 in alopecia areata with no dose-limiting toxicities; a full readout is expected by Q4 2026.
- Product and commercial shift: Reclaimed rights to HCW9201/9206 and is repositioning them as manufacturing reagents for cell‑based therapies targeting commercialization opportunities.
- Pipeline advancement: Preparing IND-enabling studies and planning a Type B pre‑IND engagement for HCW11-018b, a T‑cell engager, with a Phase 1 start aimed for H1 2027.
- Operational restructuring and partnerships: Settled key vendor liabilities and is pursuing commercialization partnerships for reagents alongside CDMO GMP manufacturing plans.
Original SEC Filing: HCW Biologics Inc. [ HCWB ] - 10-Q - Aug. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.